Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Xenon Gas Inhalation in Healthy Volunteers
NCT06945614Phase 1Recruiting
- Sponsor
- General Biophysics
- Start
- Apr 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of xenon in Alzheimer's disease (AD) (4 arms), sponsored by General Biophysics. Primary endpoint: Number of Participants with Xenon Treatment-Related Adverse Events at Each Treatment Duration as Assessed by CTCAE v4.0 at 7 days. Started Apr 2025; status: recruiting.
02
Drugs
xenon
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06945614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06945614.